Gilead Sciences has announced an $11 billion investment to enhance its U.S. manufacturing and research capabilities. This move is in response to anticipated tariffs from the Trump administration, which is currently investigating the pharmaceutical sector. The investment is part of a broader industry trend, with companies like Johnson & Johnson, Merck, and Novartis collectively pledging over $200 billion to bolster domestic operations .(Reuters, WSJ)
The $11 billion will supplement Gilead’s existing $21 billion commitment through 2030, totaling $32 billion in U.S. investments. The funds will support the construction of three new facilities, upgrades to three existing sites, and advancements in technology and engineering. These efforts are expected to create at least 800 direct jobs and over 2,200 indirect jobs by 2028, generating approximately $43 billion in economic value over the next five years .(WSJ, Reuters)
This strategic investment underscores Gilead’s commitment to strengthening its domestic operations and responding proactively to the evolving regulatory landscape.
